Find disease awareness content and relevant supporting materials

This review evaluates the impact of non-pharmacologic therapies on systemic lupus erythematosus (SLE), highlighting improvements in fatigue, depression, pain, and quality of life, but no significant changes in disease activity.

Attention-deficit/hyperactivity disorder (ADHD) is a common disorder of childhood that often persists into adulthood. Although stimulant medications are recommended as the first-line treatment for ADHD because of their...

Emerging neuromodulation devices show promise for expanding acute treatment options. Over the past few years, there has been a growth in research investigating the efficacy and safety of non-invasive neuromodulation, which delivers electrical or magnetic stimulation to nerves or neural tissue, for the management of acute attacks of migraine

What is known and objective: Previous studies based on small-sample clinical data proved that short-term use of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors increased haemoglobin levels in anaemic patients with chronic kidney disease (CKD).

Purpose: To review the literature and provide recommendations on diet and lifestyle considerations in patients with prostate cancer using evidence from randomized controlled trials (RCTs) with additional considerations...

Esketamine, approved by the FDA in 2019, offers a new treatment option for adults with treatment-resistant depression (TRD). This review evaluates its efficacy and safety based on clinical trials, highlighting both its rapid antidepressant effects and potential safety concerns.

Objectives: To examine the efficacy of plasma exchange in the short and long term treatment of myasthenia gravis.

Background: Patients with moderate-to-severe psoriasis require long-term treatment, yet few trials compare outcomes beyond a short-term induction period. Quantitative comparisons of long-term outcomes in patients with psoriasis are limited. To our knowledge, no network meta-analysis (NMA) of such data has been performed.

Shionogi presented positive results of a 52-week, placebo-controlled, phase III study (COMPOSE III) of S 297995 (naldemedine) in treating opioid-induced...